Johnson & Johnson Innovation and the Biomedical Advanced Research and Development Authority (BARDA) have announced the ‘Blue Knight Resident QuickFire Challenge: Accel
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS